United Therapeutics Shares (Diluted) decreased by 0.2% to 47.2M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 2.9%, from 48.6M to 47.2M. This is a positive signal — lower values indicate better performance for this metric.
An increase indicates potential dilution from employee compensation or convertible instruments, which can reduce earnings per share.
The weighted-average number of common shares outstanding plus the effect of all potentially dilutive securities, such as...
Standard metric for all public companies; essential for understanding the impact of equity-based compensation.
weighted_shares_diluted| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 47.3M | 47.6M | 47.7M | 48.1M | 48.7M | 49.6M | 49.5M | 49.7M | 49.7M | 47.5M | 48.4M | 48.6M | 48.3M | 47.3M | 47.2M |
| QoQ Change | — | +0.6% | +0.2% | +0.8% | +1.2% | +1.8% | -0.2% | +0.4% | +0.0% | -4.4% | +1.9% | +0.4% | -0.6% | -2.1% | -0.2% |
| YoY Change | — | — | — | +1.7% | +2.3% | +4.0% | +2.9% | +2.1% | +0.2% | -4.0% | -2.6% | -2.2% | +1.7% | -2.3% | -2.9% |